WeightControl.com: What are the main findings?
Response: GLP‐1 analog treatment does increase visceral adipose tissue (VAT) metabolic activity in the patients we studied. The degree of increase correlated with the amount of weight lost and low VAT metabolic activity at baseline was a predictor of good response to treatment with GLP‐1 in our study.
WeightControl.com: What should readers take away from your report?
Response: Treatment of obesity is more complicated than simply eat less and move more – and these newer GLP-1 based therapies are increasing fat tissue metabolism as well as making you eat less.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: More work on the mechanism of GLP‐1 regulation of VAT metabolic activity is needed to inform our understanding of the how these newer gut hormone based agents impact on weight change. Understanding this might help with product development that minimises the side effects of nausea and constipation while maximising the treatment benefits for obesity.
Disclosures: National Lead in Ireland for Management of Obesity and Advisor to WHO Europe on Obesity
Citation:
ObesityWeek abstract:
https://obesityweek.org/abstracts/
GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 6, 2024 by weightcontrol